Values are displayed in Millions | Trend | 12/31/2016 | 12/31/2017 | 12/31/2018 | N/A |
---|---|---|---|---|---|
Net Revenues | 265 | 430 | 740 | N/A | |
Cost of Goods Sold | 188 | 320 | 600 | N/A | |
Depreciation And Amortization | 16 | 26 | 42 | N/A | |
Gross Income | 62 | 84 | 98 | N/A | |
General Expenses | 35 | 52 | 77 | N/A | |
Other Operating Expenses | 0 | 0 | 0 | N/A | |
Research And Development | 0 | N/A | N/A | N/A | |
Total Operating Expenses | 238 | 398 | 719 | N/A | |
Operating Income | 27 | 32 | 21 | N/A | |
Extraordinary Credit | 0 | 0 | 1 | N/A | |
Extraordinary Charge | 0 | 0 | 0 | N/A | |
Pre-Tax Equity Earnings | 3 | 0.86 | 2 | N/A | |
Interest Expense On Debt | 6 | 18 | 33 | N/A | |
Other Expenses | 0 | 0 | 0 | N/A | |
Pre-Tax Income | 23 | 15 | -9 | N/A | |
Income Taxes | 0 | 0 | -2 | N/A | |
Minority Interest | -2 | -2 | -2 | N/A | |
Net Income Before Preferreds and Extraordinary Items | 21 | 13 | -9 | N/A | |
Preferred Dividend | 0 | 0 | 0 | N/A | |
Discontinued Operations | 0 | 0 | 0 | N/A | |
Extraordinary Items | 0 | 0 | 0 | N/A | |
Income Available for Common | 21 | 13 | -9 | N/A | |
Shares To Calculate EPS | 30 | 30 | 27 | N/A | |
Shares To Calculate EPS Diluted | 30 | 30 | 27 | N/A | |
EPS | 0.70 | 0.43 | -0.33 | N/A | |
EPS Diluted | 0.70 | 0.43 | -0.33 | N/A | |
Filing Type | Filing Category | Filing Date |
---|---|---|
8-K | Company Events | 01/20/2023 |
8-K | Company Events | 12/30/2022 |
DEF 14C | DEF 14C | 12/08/2022 |
8-K | Company Events | 12/06/2022 |
SC 13D/A | SC 13D/A | 11/23/2022 |
3/A | 3/A | 11/23/2022 |
PRE 14C | PRE 14C | 11/23/2022 |
4 | Insider Buy/Sell | 11/23/2022 |
4 | Insider Buy/Sell | 11/22/2022 |
SC 13G/A | >= 5% Acquisition | 11/22/2022 |
3 | New Insider | 11/21/2022 |
3 | New Insider | 11/21/2022 |
3 | New Insider | 11/21/2022 |
4 | Insider Buy/Sell | 11/21/2022 |
4 | Insider Buy/Sell | 11/18/2022 |
SC 13D/A | SC 13D/A | 11/18/2022 |
4 | Insider Buy/Sell | 11/17/2022 |
8-K | Company Events | 11/16/2022 |
4 | Insider Buy/Sell | 11/16/2022 |
8-K | Company Events | 11/15/2022 |